Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment